Cite
What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?
MLA
De Lorenzis, Enrico, et al. “What Can We Learn from Rapidly Progressive Interstitial Lung Disease Related to Anti-MDA5 Dermatomyositis in the Management of COVID-19?” Autoimmunity Reviews, vol. 19, no. 11, Nov. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.autrev.2020.102666.
APA
De Lorenzis, E., Natalello, G., Gigante, L., Verardi, L., Bosello, S. L., & Gremese, E. (2020). What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? Autoimmunity Reviews, 19(11), N.PAG. https://doi.org/10.1016/j.autrev.2020.102666
Chicago
De Lorenzis, Enrico, Gerlando Natalello, Laura Gigante, Lucrezia Verardi, Silvia Laura Bosello, and Elisa Gremese. 2020. “What Can We Learn from Rapidly Progressive Interstitial Lung Disease Related to Anti-MDA5 Dermatomyositis in the Management of COVID-19?” Autoimmunity Reviews 19 (11): N.PAG. doi:10.1016/j.autrev.2020.102666.